title: Addressing concerns about cisplatin application during pregnancy.
abstract: Cervical cancer in second trimester of pregnancy is an oncologic challenge. Cisplatin is recommended to prevent cancer progression. This is a series correlating in vivo cisplatin concentration in the fetomaternal compartment and in breast milk with child development.
  
  
  
  Eight consecutive patients with cervical cancer diagnosed during the second trimester underwent conization/biopsy and/or pelvic laparoscopic lymphadenectomy (LAE). Delay of pregnancy in combination with neoadjuvant monochemotherapy was performed. After 2-4 cycles of cisplatin monochemotherapy cesarean section followed by radical hysterectomy was performed above 31 weeks of gestation. Synchronous samples from maternal blood, umbilical cord blood, and amniotic fluid were taken and analyzed. A probe of breast milk was taken from three patients. Pediatric aftercare was done every three months postpartum.
  
  
  
  Laparoscopic LAE was uncomplicated in all patients. In seven out of eight patients lymph nodes were tumor free. Nine healthy babies were delivered. Pediatric follow-up showed normal development. Cisplatin concentrations in the umbilical cord and amniotic fluid were 31-65% and 13-42% of the amount in maternal blood, respectively. In breast milk, cisplatin was detectable in 1-10% of maternal blood concentration.
  
  
  
  Knowledge of significant lower cisplatin concentrations in fetal compartment and normal child growth provides additional security to apply cisplatin in pregnancy. Breastfeeding cannot be recommended.
authors.affiliation: Department of Gynecology, Charité Universitätsmedizin, Berlin, Germany. malgorzata.lanowska@charite.de
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Lanowska
authors.forename: Christhardt
authors.initials: C
authors.lastname: Köhler
authors.forename: Peter
authors.initials: P
authors.lastname: Oppelt
authors.forename: Alexander
authors.initials: A
authors.lastname: Schmittel
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Gottschalk
authors.forename: Kati
authors.initials: K
authors.lastname: Hasenbein
authors.forename: Achim
authors.initials: A
authors.lastname: Schneider
authors.forename: Simone
authors.initials: S
authors.lastname: Marnitz
mesh_terms: D000328:Adult; D000653:Amniotic Fluid / Q000737:chemistry; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002585:Cesarean Section; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects* / Q000032:analysis; D019092:Conization; D005260:Female; D005312:Fetal Blood / Q000737:chemistry; D005865:Gestational Age; D006801:Humans; D007044:Hysterectomy; D007231:Infant, Newborn; D008197:Lymph Node Excision; D008895:Milk, Human / Q000737:chemistry; D049268:Positron-Emission Tomography; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D011256:Pregnancy Outcome; D011262:Pregnancy Trimester, Second; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin